RevX 2025: Philadelphia
The Next Chapter: How AI Will Reshape R&D in 2025 and Beyond
Shahram Ebadollahi Principal, Nav.AI - Former CDAO, Novartis
Chris McSpiritt VP of Life Sciences Strategy, Domino
This session explores what it really takes to move beyond AI pilots and embed AI into the core of life sciences R&D. From rethinking workflows and leadership models to balancing innovation with compliance, Shahram Ebadollahi (former Novartis CDAO) outlines the cultural, technical, and strategic foundations needed to unlock scalable, enterprise-wide impact with AI.
Key Takeaways
- AI success isn’t just about tools. It’s about transforming how work gets done. Leadership buy-in, incentive alignment, and change management are as critical as the models themselves.
- R&D acceleration comes from embedding AI into workflows, not layering it on top. Organizations must redesign processes like molecule triage, trial planning, and formulation to be “AIable” from the start.
- Compliance and innovation can coexist with the right governance model. Regulatory guardrails, human-in-the-loop systems, and cross-functional oversight ensure AI-driven decisions are trustworthy and traceable.